...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Additional Reports Of Exempt Distribution.

Thanks for that RVXOT, that seems fairly clear although given what Jonzobot had said regarding blackouts I guess it really doesn't matter. As I said I have seen companies raise money during a blackout period. I was basing my statement on what Don had said at the time of the spin-off (ie that it was a "widely held private co"). Really no big deal I guess. 

Share
New Message
Please login to post a reply